This is a positive step towards equity. However, like all recommendations it comes down the the effectiveness of implementation and the fact that the true cost of research is never covered by our funding models. Will be interesting to see how big pharma adopt these. @PeterMacRes
For the first time, WHO offers recommendations for national health authorities, regulators, and funders to improve clinical trials.View quoted post on X
The guidance addresses issues like poor trial design, lack of diversity and inclusion of at-risk populations, infrastructure gaps, and inefficiencies that delay progress.
bit.ly/4eEZSjn